# IMCR catalysts: Immunocore Holdings plc PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/imcr/catalysts

> Immunocore Holdings plc (IMCR) has 5 upcoming catalysts. The next is the KIMMTRAK (tebentafusp) topline data readout, Q2 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only, year only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for IMCR?

Immunocore Holdings plc (IMCR) has 5 upcoming catalysts. The next is the KIMMTRAK (tebentafusp) topline data readout, Q2 2027. Press release filed with the SEC (EX-99): "Phase 3 TEBE-AM trial for previously treated advanced cutaneous melanoma completed target enrollment of 540 patients - Topline overall survival data expected second quarter of 2027" [Calendar and source filings](https://sec-api.dev/companies/imcr/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001671927-26-000034, https://www.sec.gov/Archives/edgar/data/1671927/000167192726000034/pressrelease-q32026.htm (retrieved 2026-11-12). Last confirmed 2026-11-06. Cite: https://sec-api.dev/companies/imcr/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Immunocore Holdings plc |
| Ticker | IMCR (Nasdaq) |
| SEC CIK | 1671927 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/imcr |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| January 25, 2022 | [Kimmtrak (tebentafusp-tebn) FDA approval](https://sec-api.dev/pdufa/tebentafusp-tebn) | IMCR | To treat unresectable or metastatic uveal melanoma | completed, approved | "Kimmtrak \| tebentafusp-tebn \| 1/25/2022 \| To treat unresectable or metastatic uveal melanomaDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022)) |
| Apr 2022 | [KIMMTRAK (tebentafusp) FDA approval](https://sec-api.dev/pdufa/tebentafusp) | IMCR | unresectable or metastatic uveal melanoma | completed, approved | "In January and April 2022, the Company received approval from the U.S. Food and Drug Administration ("FDA") and European Commission ("EC"), respectively, for its lead product, KIMMTRAK, for the treatment of unresectable or metastatic uveal melanoma." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1671927/000167192725000018/imcr-20250930.htm)) |
| Q1 2025 | [Immunocore Holdings plc interim data readout](https://sec-api.dev/companies/imcr/catalysts) | IMCR |  | scheduled | "The Company continues to enroll people living with HIV (PLWH) in the multiple ascending dose (MAD) part of the Phase 1 clinical trial with IMC-M113V and will present initial data during the first quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671927/000114036125000837/ef20041400_ex99-1.htm)) |
| January 10, 2025 | [Immunocore Holdings plc earnings report](https://sec-api.dev/companies/imcr/catalysts) | IMCR |  | completed | "Immunocore will report its final and complete fourth-quarter and full-year 2024 financial results in late February 2025, and the actual results could be different from these preliminary unaudited financial results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671927/000114036125000837/ef20041400_ex99-1.htm)) |
| February 25, 2025 | [Immunocore Holdings plc earnings report](https://sec-api.dev/companies/imcr/catalysts) | IMCR |  | completed | "Immunocore reports fourth quarter and full year 2024 financial results and provides a business update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671927/000114036125005988/ef20044296_ex99-1.htm)) |
| May 7, 2025 | [Immunocore Holdings plc earnings report](https://sec-api.dev/companies/imcr/catalysts) | IMCR |  | completed | "Immunocore reports first quarter financial results and provides a business update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671927/000114036125017615/ef20048471_ex99-1.htm)) |
| August 7, 2025 | [Immunocore Holdings plc earnings report](https://sec-api.dev/companies/imcr/catalysts) | IMCR |  | completed | "Immunocore reports second quarter financial results and provides a business update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671927/000114036125029350/ef20053240_ex99-1.htm)) |
| November 6, 2025 | [Immunocore Holdings plc earnings report](https://sec-api.dev/companies/imcr/catalysts) | IMCR |  | completed | "Immunocore reports third quarter financial results and provides a business update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671927/000114036125040664/ef20058378_ex99-1.htm)) |
| 2026 | [Brenetafusp topline data readout](https://sec-api.dev/pdufa/brenetafusp) | IMCR |  | scheduled | "We anticipate topline results for the first of these three pivotal trials in 2026," said Bahija Jallal, Immunocore's Chief Executive Officer." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671927/000114036125000837/ef20041400_ex99-1.htm)) |
| January 9, 2026 | [Immunocore Holdings plc earnings report](https://sec-api.dev/companies/imcr/catalysts) | IMCR |  | completed | "Immunocore will report its final and complete fourth-quarter and full-year 2025 financial results in late February 2026, and the actual results could be different from these preliminary unaudited financial results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671927/000114036126000780/ef20062561_ex99-1.htm)) |
| February 25, 2026 | [Immunocore Holdings plc earnings report](https://sec-api.dev/companies/imcr/catalysts) | IMCR |  | completed | "Immunocore reports fourth quarter and full year 2025 financial results and provides a business update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671927/000114036126006721/ef20066378_ex99-1.htm)) |
| May 6, 2026 | [Immunocore Holdings plc earnings report](https://sec-api.dev/companies/imcr/catalysts) | IMCR |  | completed | "Immunocore reports first quarter financial results and provides a business update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671927/000114036126019205/ef20072537_ex99-1.htm)) |
| 2H 2026 | [Brenetafusp interim data readout](https://sec-api.dev/pdufa/brenetafusp) | IMCR |  | scheduled | "In the second half of 2026, the Company expects to present data from the ongoing ovarian and NSCLC expansion cohorts of the Phase 1/2 trial of brenetafusp and the initial data from the half-life extended PRAME-A02 candidate (IMC-P115C)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671927/000114036126006721/ef20066378_ex99-1.htm)) |
| 2H 2026 | [Yervoy® (ipilimumab) topline data readout](https://sec-api.dev/pdufa/ipilimumab) | IMCR |  | scheduled | "We expect the Phase 3 trial to complete patient enrollment in the first half of 2026 with topline data expected as early as the second half of 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1671927/000167192726000005/imcr-20251231.htm)) |
| August 6, 2026 | [Immunocore Holdings plc earnings report](https://sec-api.dev/companies/imcr/catalysts) | IMCR |  | completed | "Immunocore reports second quarter financial results and provides a business update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671927/000167192726000020/pressrelease-q22026.htm)) |
| late 2026 | [KIMMTRAK (tebentafusp) topline data readout](https://sec-api.dev/pdufa/tebentafusp) | IMCR | cancer, infectious diseases and autoimmune diseases, today | scheduled | "TEBE-AM enrollment completion anticipated 1H 2026 with topline data expected as early as 2H 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671927/000114036126006721/ef20066378_ex99-1.htm)) |
| November 6, 2026 | [Immunocore Holdings plc earnings report](https://sec-api.dev/companies/imcr/catalysts) | IMCR |  | completed | "Immunocore reports third quarter financial results and provides a business update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671927/000167192726000034/pressrelease-q32026.htm)) |
| Q2 2027 | [KIMMTRAK (tebentafusp) topline data readout](https://sec-api.dev/pdufa/tebentafusp) | IMCR |  | scheduled | "Phase 3 TEBE-AM trial for previously treated advanced cutaneous melanoma completed target enrollment of 540 patients - Topline overall survival data expected second quarter of 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671927/000167192726000034/pressrelease-q32026.htm)) |
| Oct 2027 to Jan 2028 | [Brenetafusp topline data readout](https://sec-api.dev/pdufa/brenetafusp) | IMCR | Advanced Melanoma | scheduled | "NCT06112314 (IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-16 (ESTIMATED); Lead Sponsor Immunocore Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06112314)) |
| October 2027 | [Brenetafusp primary completion](https://sec-api.dev/pdufa/brenetafusp) | IMCR | Advanced Melanoma | scheduled | "NCT06112314 (IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-16 (ESTIMATED); Lead Sponsor Immunocore Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06112314)) |
| March 2028 | [KIMMTRAK (tebentafusp) primary completion](https://sec-api.dev/pdufa/tebentafusp) | IMCR | Advanced Melanoma | scheduled | "NCT05549297 (Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Immunocore Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05549297)) |
| Mar to Jun 2028 | [KIMMTRAK (tebentafusp) topline data readout](https://sec-api.dev/pdufa/tebentafusp) | IMCR | Advanced Melanoma | scheduled | "NCT05549297 (Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Immunocore Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05549297)) |

## Drugs

- [Brenetafusp](https://sec-api.dev/pdufa/brenetafusp): Advanced Melanoma
- [KIMMTRAK (tebentafusp)](https://sec-api.dev/pdufa/tebentafusp): unresectable or metastatic uveal melanoma, cancer, infectious diseases and autoimmune diseases, today, previously treated advanced cutaneous melanoma, Advanced Melanoma
- [Kimmtrak (tebentafusp-tebn)](https://sec-api.dev/pdufa/tebentafusp-tebn): To treat unresectable or metastatic uveal melanoma

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/imcr/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "IMCR catalysts: Immunocore Holdings plc PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/imcr/catalysts

```bibtex
@misc{secapidev_companies_imcr_catalysts_20261116,
  title        = {IMCR catalysts: Immunocore Holdings plc PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/imcr/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_imcr_catalysts_20261116","title":"IMCR catalysts: Immunocore Holdings plc PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/imcr/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
